What is repatha used for
Searched over 200M research papers
Summary
8 papers analyzed
These studies suggest Repatha is used to treat various forms of hypercholesterolemia, including primary, mixed dyslipidemia, and familial hypercholesterolemia, particularly in patients who cannot achieve LDL-C goals with statins alone.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Uses of Repatha (Evolocumab)
Treatment for Hypercholesterolemia
Primary Hypercholesterolemia and Mixed Dyslipidemia
Repatha (evolocumab) is primarily used to treat hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It is effective in reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolemia, including both heterozygous familial and non-familial forms, as well as mixed dyslipidemia . Repatha works by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), which enhances the liver's ability to remove LDL-C from the bloodstream .
Homozygous Familial Hypercholesterolemia
Repatha is also approved for use in patients with homozygous familial hypercholesterolemia (HoFH), a more severe form of hypercholesterolemia. In clinical trials, it has been shown to significantly lower LDL-C levels in these patients when used in combination with other lipid-lowering therapies, including statins and ezetimibe .
Adjunct to Statin Therapy
Statin-Intolerant Patients
For patients who are intolerant to statins, Repatha offers an alternative treatment option. It can be used as monotherapy or in combination with other lipid-lowering agents to achieve significant reductions in LDL-C levels . This makes it a valuable option for patients who cannot tolerate the side effects of statins or who do not achieve their LDL-C targets with statins alone .
Combination with Statins
Repatha is often used as an adjunct to diet and maximally tolerated statin therapy in adults with clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who require additional lowering of LDL-C . Clinical trials have demonstrated that Repatha, when added to statin therapy, can reduce LDL-C levels by up to 60%.
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Cardiovascular Event Reduction
Repatha has been shown to significantly reduce the incidence of major cardiovascular adverse events in patients with atherosclerotic cardiovascular disease who have residual hypercholesterolemia despite statin therapy. The FOURIER trial demonstrated a 15% reduction in major cardiovascular events, highlighting its role in secondary prevention. This makes Repatha a critical option for patients at high risk of cardiovascular events who need additional LDL-C lowering beyond what statins can provide.
Safety and Tolerability
Clinical Trial Outcomes
Repatha has been well-tolerated in clinical trials, with a safety profile comparable to placebo and other lipid-lowering therapies. It has shown no significant adverse effects on cognitive function and has been effective in long-term use . This favorable safety profile supports its use in a broad range of patients, including those with very low LDL-C levels.
Conclusion
Repatha (evolocumab) is a versatile and effective treatment for various forms of hypercholesterolemia, particularly in patients who do not achieve their LDL-C targets with statins alone or who are statin-intolerant. Its ability to significantly lower LDL-C levels and reduce the risk of cardiovascular events makes it a valuable addition to lipid-lowering therapy regimens.
Sources and full results
Most relevant research papers on this topic
